-
公开(公告)号:US20240337668A1
公开(公告)日:2024-10-10
申请号:US18632426
申请日:2024-04-11
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Saul Datwyler , Raj Chandran , Jaime Marino
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2333/435 , G01N2333/948 , G01N2800/28
Abstract: Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
-
22.
公开(公告)号:US20240110928A1
公开(公告)日:2024-04-04
申请号:US18474826
申请日:2023-09-26
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Saul Datwyler , Raj Chandran
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/916 , G01N2800/28 , G01N2800/56
Abstract: Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.
-
公开(公告)号:US20230213536A1
公开(公告)日:2023-07-06
申请号:US18147094
申请日:2022-12-28
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Saul Datwyler , Raj Chandran
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/56 , G01N2800/28
Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
-
公开(公告)号:US20210072243A1
公开(公告)日:2021-03-11
申请号:US17095695
申请日:2020-11-11
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Justin Rogers , Saul Datwyler , Jaime Marino
IPC: G01N33/573 , G01N33/68 , A61B6/03 , A61B6/00
Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.
-
公开(公告)号:US20210059594A1
公开(公告)日:2021-03-04
申请号:US17084568
申请日:2020-10-29
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Frederick Korley , Agim Beshiri , Jaime Marino , Saul Datwyler
IPC: A61B5/00 , G01N33/68 , G01N33/543 , G01N33/577
Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
-
公开(公告)号:US20180313837A1
公开(公告)日:2018-11-01
申请号:US15934541
申请日:2018-03-23
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Justin Rogers , Saul Datwyler , Jaime Marino
IPC: G01N33/573 , A61B6/03 , A61B6/00
CPC classification number: G01N33/6896
Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
-
公开(公告)号:US20250020672A1
公开(公告)日:2025-01-16
申请号:US18795240
申请日:2024-08-06
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Justin Rogers , Saul Datwyler , Jaime Marino
IPC: G01N33/68 , G01N33/573
Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.
-
公开(公告)号:US20250020666A1
公开(公告)日:2025-01-16
申请号:US18804253
申请日:2024-08-14
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Saul A. Datwyler , Raj Chandran
IPC: G01N33/68
Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
-
公开(公告)号:US20240298956A1
公开(公告)日:2024-09-12
申请号:US18588150
申请日:2024-02-27
Applicant: Abbott Laboratories
Inventor: Beth McQuiston , Frederick Korley , Agim Beshiri , Jaime Marino , Saul Datwyler
IPC: A61B5/00 , C12Q1/6883 , G01N33/533 , G01N33/543 , G01N33/564 , G01N33/577 , G01N33/68
CPC classification number: A61B5/4064 , G01N33/54346 , G01N33/54366 , G01N33/577 , G01N33/6896 , C12Q1/6883 , G01N33/533 , G01N33/564 , G01N33/6893 , G01N2800/28 , G01N2800/52 , G01N2800/56 , G01N2800/60
Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
-
公开(公告)号:US11994523B2
公开(公告)日:2024-05-28
申请号:US17224685
申请日:2021-04-07
Applicant: Abbott Laboratories , Cedars-Sinai Medical Center
Inventor: Jennifer Van Eyk , Beth McQuiston , Saul Datwyler , Raj Chandran , Vidya Venkatraman , Shenyan Zhang
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2560/00 , G01N2800/28 , G01N2800/50 , G01N2800/52 , G01N2800/60
Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.
-
-
-
-
-
-
-
-
-